External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>AIL reported revenue growth of 15.9% in Q2FY22, outpacing the IPM (Indian Pharma Industry, Source: AIOCD) growth of 14.6%</li><li>The company’s Gross Margins improved by 110bps due to a richer product mix and pass on the increase in raw material prices</li><li>We recommend a BUY rating on the stock with a Target Price of Rs 22,400/share.</li></ul><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

AIL reported revenue growth of 15.9% in Q2FY22, outpacing the IPM (Indian Pharma Industry, Source: AIOCD) growth of 14.6%The company’s Gross Margins improved by 110bps due to a richer product mix and pass on the increase in raw material pricesWe recommend a BUY rating on the stock with a Target Price of Rs 22,400/share.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Abbott India: Key Therapies Report Robust Sales Improvement

<p>We expect Revenue/PAT CAGR of 11.1%/11.3% respectively over FY21-FY24E. While a TP of Rs 20,000 implies a marginal downside of 2.5%, we remain positive on the long-term outlook of the company and recommend a HOLD rating on the stock.</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

We expect Revenue/PAT CAGR of 11.1%/11.3% respectively over FY21-FY24E. While a TP of Rs 20,000 implies a marginal downside of 2.5%, we remain positive on the long-term outlook of the company and recommend a HOLD rating on the stock.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Abbott India: Sustainable Performance Gaining Market Share

<p>We expect stable sales in the Duphaston brand and an increase in volume in the Thyronorm brand to result in revenue and PAT CAGR of 11.1% and 11.3% respectively 0ver FY21-FY24E. However, considering rich valuations (PE 40x for FY24E), we recommend HOLD with a target price of Rs 18,000/share.</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

We expect stable sales in the Duphaston brand and an increase in volume in the Thyronorm brand to result in revenue and PAT CAGR of 11.1% and 11.3% respectively 0ver FY21-FY24E. However, considering rich valuations (PE 40x for FY24E), we recommend HOLD with a target price of Rs 18,000/share.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Abbott India: Sales Improvement in Key Therapies

India

Abbott India Limited manufactures a wide range of pharmaceutical and medical products, agrochemicals, and animal health products. The Company's medical and pharmaceutical products include insulin injections, anti-dysentery drugs, vitamin preparations, penicillin preparations, sulfonamide tablets, and a variety of household remedies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Abbott India (BOOT IN)

Abbott India: Key Therapies Report Robust Sales Improvement

AIL reported revenue growth of 15.9% in Q2FY22, outpacing the IPM (Indian Pharma Industry, Source: AIOCD) growth of 14.6%.

Axis Direct

Abbott India: Sales Improvement in Key Therapies

We expect stable sales in the Duphaston brand and an increase in volume in the Thyronorm brand to result in revenue and PAT CAGR of 11.1% and 11.3%...

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Abbott India: Key Therapies Report Robust Sales Improvement

AIL reported revenue growth of 15.9% in Q2FY22, outpacing the IPM (Indian Pharma Industry, Source: AIOCD) growth of 14.6%.

Axis Direct

Abbott India: Sustainable Performance Gaining Market Share

We expect Revenue/PAT CAGR of 11.1%/11.3% respectively over FY21-FY24E. While a TP of Rs 20,000 implies a marginal downside of 2.5%, we remain...

Axis Direct

Abbott India: Sales Improvement in Key Therapies

We expect stable sales in the Duphaston brand and an increase in volume in the Thyronorm brand to result in revenue and PAT CAGR of 11.1% and 11.3%...

Axis Direct